Dianthus Therapeutics, Inc. (DNTH) Competitors & Peers
The 5 largest companies in the same industry as Dianthus Therapeutics, Inc., by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| VRTX | Peer | $550.87 | P/E 35.5RSI 58Cap 139.8 B |
| REGN | Peer | $919.96 | P/E 20.8RSI 72Cap 97.3 B |
| ARGX | Peer | $962.27 | P/E 33.3RSI 62Cap 60.7 B |
| RVMD | Peer | $200.15 | RSI 55Cap 42.6 B |
| CSLLY | Peer | $35.11 | P/E 18.2RSI 71Cap 66.6 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- AZNCompetitor
Dianthus' DNTH103 competes with AstraZeneca's Soliris/Ultomiris products.
Model-inferred, unverified — treat as a lead, not evidence